Abstract
Hypereosinophilic syndromes in children are rare disorders traditionally characterized by an eosinophil count exceeding 1,500/mm³ on at least 2 occasions or evidence of tissue eosinophilia associated with symptoms and marked blood eosinophilia, lacking any secondary cause (such as infections, allergic disease, chemical-induced eosinophilia, hypoadrenalism, cancer). Until now there have only been 3 reported cases of pediatric FIP1L1-PDGFRα-positive hypereosinophilic syndromes. We describe a fourth patient, a white 14-year-old boy, the third treated with imatinib.
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
-
Review
MeSH terms
-
Adolescent
-
Age of Onset
-
Antineoplastic Agents / therapeutic use
-
Benzamides / therapeutic use
-
Bone Marrow / pathology*
-
Humans
-
Hypereosinophilic Syndrome / drug therapy
-
Hypereosinophilic Syndrome / genetics*
-
Hypereosinophilic Syndrome / pathology*
-
Imatinib Mesylate
-
Male
-
Oncogene Proteins, Fusion / genetics*
-
Piperazines / therapeutic use
-
Pyrimidines / therapeutic use
-
Receptor, Platelet-Derived Growth Factor alpha / genetics*
-
mRNA Cleavage and Polyadenylation Factors / genetics*
Substances
-
Antineoplastic Agents
-
Benzamides
-
Oncogene Proteins, Fusion
-
Piperazines
-
Pyrimidines
-
mRNA Cleavage and Polyadenylation Factors
-
Imatinib Mesylate
-
FIP1L1-PDGFRA fusion protein, human
-
Receptor, Platelet-Derived Growth Factor alpha